2024
Mechanistic Differences between Torsemide and Furosemide.
Rao V, Cox Z, Ivey-Miranda J, Neville D, Balkcom N, Moreno-Villagomez J, Ramos-Mastache D, Maulion C, Bellumkonda L, Tang W, Collins S, Velazquez E, Mentz R, Wilson F, Turner J, Wilcox C, Ellison D, Fang J, Testani J. Mechanistic Differences between Torsemide and Furosemide. Journal Of The American Society Of Nephrology 2024 PMID: 39196651, DOI: 10.1681/asn.0000000000000481.Peer-Reviewed Original ResearchTorsemide groupDiuretic doseTubular site of actionHigher diuretic dosesDose of furosemideProportion of dosesOral furosemideSite of actionPrescribed doseNeurohormonal activationMechanistic substudyClinical outcomesPharmacodynamic advantagesKidney dysfunctionPharmacodynamic parametersKidney functionRandomized trialsNatriuresisTubular sitesFurosemideTorsemideDoseTRANSFORM-HFPlasma volumeBody weightOn‐treatment analysis of torsemide versus furosemide for patients hospitalized for heart failure: A post‐hoc analysis of TRANSFORM‐HF
Kittipibul V, Mentz R, Clare R, Wojdyla D, Anstrom K, Eisenstein E, Ambrosy A, Goyal P, Skopicki H, Ketema F, Kim D, Desvigne-Nickens P, Pitt B, Velazquez E, Greene S. On‐treatment analysis of torsemide versus furosemide for patients hospitalized for heart failure: A post‐hoc analysis of TRANSFORM‐HF. European Journal Of Heart Failure 2024, 26: 1518-1523. PMID: 38745502, PMCID: PMC11269016, DOI: 10.1002/ejhf.3293.Peer-Reviewed Original ResearchOn-treatment analysisFollow-upAll-cause mortalityHeart failureOn-treatmentNo significant differenceNon-adherencePost-hocSignificant differenceTime of hospital dischargePost hoc analysisDiuretic statusPatients on-treatmentTorsemide groupOpen-labelFurosemide groupRandomized patientsTRANSFORM-HFHF hospitalizationRandomized trialsFurosemidePatientsTorsemideHospital outcomesOutcome differencesSacubitril/Valsartan in Patients Hospitalized With Decompensated Heart Failure
Morrow D, Velazquez E, Desai A, DeVore A, Lepage S, Park J, Sharma K, Solomon S, Starling R, Ward J, Williamson K, Zieroth S, Hernandez A, Mentz R, Braunwald E. Sacubitril/Valsartan in Patients Hospitalized With Decompensated Heart Failure. Journal Of The American College Of Cardiology 2024, 83: 1123-1132. PMID: 38508844, DOI: 10.1016/j.jacc.2024.01.027.Peer-Reviewed Original ResearchConceptsWorsening heart failureHeart failureEjection fractionNT-proBNPSpectrum of EFPIONEER-HFSpectrum of left ventricular ejection fractionRandomized trialsTime-averaged proportional changeN-terminal pro-B-type natriuretic peptidePro-B-type natriuretic peptideLeft ventricular ejection fractionWorsening heart failure eventDecompensated heart failureVentricular ejection fractionPlasma NT-proBNPPIONEER-HF trialDouble-blindMedian ageMedian EFSNatriuretic peptideSymptomatic hypotensionBaseline characteristicsClinical outcomesPooled analysisEfficacy And Safety Of Sacubitril/valsartan In Patients Hospitalized With Heart Failure: A Prespecified, Pooled Individual Patient-level Analysis Of PIONEER-HF And PARAGLIDE-HF
Morrow D, Velazquez E, Desai A, DeVore A, Lepage S, Park J, Sharma K, Solomon S, Starling R, Ward J, Williamson K, Zieroth S, Hernandez A, Mentz R, Braunwald E. Efficacy And Safety Of Sacubitril/valsartan In Patients Hospitalized With Heart Failure: A Prespecified, Pooled Individual Patient-level Analysis Of PIONEER-HF And PARAGLIDE-HF. Journal Of Cardiac Failure 2024, 30: 312-313. DOI: 10.1016/j.cardfail.2023.10.467.Peer-Reviewed Original ResearchSacubitril/valsartanPIONEER-HFHeart failurePooled analysisNT-proBNPControl therapyDe novo heart failurePlasma NT-proBNP levelsIndependent clinical events committeeIndividual patient-level analysisNovo heart failureNT-proBNP levelsClinical events committeePatient-level analysisCardiovascular deathHemodynamic stabilizationPrimary endpointSymptomatic hypotensionRenal functionMedian ageClinical outcomesRandomized trialsClinical effectsEvents committeeHF events
2015
Comparative effectiveness of torsemide versus furosemide in heart failure patients: insights from the PROTECT trial
Mentz RJ, Velazquez EJ, Metra M, McKendry C, Chiswell K, Fiuzat M, Givertz MM, Voors AA, Teerlink JR, O'Connor CM. Comparative effectiveness of torsemide versus furosemide in heart failure patients: insights from the PROTECT trial. Future Cardiology 2015, 11: 585-595. PMID: 26403536, PMCID: PMC5558519, DOI: 10.2217/fca.15.56.Peer-Reviewed Original ResearchConceptsPROTECT trialComparative effectivenessHigher blood urea nitrogenEffects of torsemideProspective randomized trialsHeart failure patientsBlood urea nitrogenGreater disease severityDays postdischargeFailure patientsHeart failureLoop diureticsRandomized trialsRenal hospitalizationUrea nitrogenDisease severityPatientsFurosemideInverse probabilityTorsemideTrialsDeathOutcomesHospitalizationDiureticsOutcomes of Anatomical versus Functional Testing for Coronary Artery Disease
Douglas PS, Hoffmann U, Patel MR, Mark DB, Al-Khalidi HR, Cavanaugh B, Cole J, Dolor RJ, Fordyce CB, Huang M, Khan MA, Kosinski AS, Krucoff MW, Malhotra V, Picard MH, Udelson JE, Velazquez EJ, Yow E, Cooper LS, Lee KL. Outcomes of Anatomical versus Functional Testing for Coronary Artery Disease. New England Journal Of Medicine 2015, 372: 1291-1300. PMID: 25773919, PMCID: PMC4473773, DOI: 10.1056/nejmoa1415516.Peer-Reviewed Original ResearchConceptsObstructive coronary artery diseaseCoronary artery diseaseCTA groupSymptomatic patientsArtery diseaseComposite primary end pointPrimary end-point eventEnd pointRadiation exposureInvasive cardiac catheterizationMajor procedural complicationsPrimary end pointSecondary end pointsEnd-point eventsCumulative radiation exposureMedian followChest painUnstable anginaCardiac catheterizationMore patientsProcedural complicationsClinical outcomesRandomized trialsAnatomical testingMean age
2014
PROspective Multicenter Imaging Study for Evaluation of chest pain: Rationale and design of the PROMISE trial
Douglas PS, Hoffmann U, Lee KL, Mark DB, Al-Khalidi HR, Anstrom K, Dolor RJ, Kosinski A, Krucoff MW, Mudrick DW, Patel MR, Picard MH, Udelson JE, Velazquez EJ, Cooper L, investigators P. PROspective Multicenter Imaging Study for Evaluation of chest pain: Rationale and design of the PROMISE trial. American Heart Journal 2014, 167: 796-803.e1. PMID: 24890527, PMCID: PMC4044617, DOI: 10.1016/j.ahj.2014.03.003.Peer-Reviewed Original ResearchConceptsCoronary artery diseasePROMISE trialAnatomical testingProspective Multicenter Imaging StudyDiagnostic strategiesInitial diagnostic strategyMajor procedural complicationsSubsequent care decisionsComposite of deathPrimary end pointLarge pragmatic trialClinical care teamQuality of lifeDiagnostic testing strategiesMultidetector coronaryChest painSymptomatic patientsUnstable anginaArtery diseaseProcedural complicationsRandomized trialsSymptomatic subjectsClinical effectivenessMyocardial infarctionPragmatic trial
2013
Low-Dose Dopamine or Low-Dose Nesiritide in Acute Heart Failure With Renal Dysfunction: The ROSE Acute Heart Failure Randomized Trial
Chen HH, Anstrom KJ, Givertz MM, Stevenson LW, Semigran MJ, Goldsmith SR, Bart B, Bull DA, Stehlik J, LeWinter MM, Konstam MA, Huggins GS, Rouleau JL, O'Meara E, Tang WH, Starling RC, Butler J, Deswal A, Felker GM, O'Connor CM, Bonita RE, Margulies KB, Cappola TP, Ofili EO, Mann DL, Dávila-Román VG, McNulty SE, Borlaug BA, Velazquez EJ, Lee KL, Shah MR, Hernandez AF, Braunwald E, Redfield MM. Low-Dose Dopamine or Low-Dose Nesiritide in Acute Heart Failure With Renal Dysfunction: The ROSE Acute Heart Failure Randomized Trial. JAMA 2013, 310: 2533-2543. PMID: 24247300, PMCID: PMC3934929, DOI: 10.1001/jama.2013.282190.Peer-Reviewed Original ResearchConceptsLow-dose dopamineAcute heart failureCumulative urine volumeRenal dysfunctionCystatin C levelsHeart failureRenal functionUrine volumeDiuretic therapyPlacebo-controlled clinical trialEnd pointPooled placebo groupCoprimary end pointsSecondary end pointsHours of admissionC levelsSerum cystatin CDose dopaminePlacebo groupActive treatmentClinical outcomesRandomized trialsClinical trialsCystatin CMAIN OUTCOME
2012
Ultrafiltration in Decompensated Heart Failure with Cardiorenal Syndrome
Bart B, Goldsmith SR, Lee KL, Givertz MM, O'Connor CM, Bull DA, Redfield MM, Deswal A, Rouleau JL, LeWinter MM, Ofili EO, Stevenson LW, Semigran MJ, Felker GM, Chen HH, Hernandez AF, Anstrom KJ, McNulty SE, Velazquez EJ, Ibarra JC, Mascette AM, Braunwald E. Ultrafiltration in Decompensated Heart Failure with Cardiorenal Syndrome. New England Journal Of Medicine 2012, 367: 2296-2304. PMID: 23131078, PMCID: PMC3690472, DOI: 10.1056/nejmoa1210357.Peer-Reviewed Original ResearchConceptsAcute decompensated heart failureDecompensated heart failureSerum creatinine levelsHeart failureUltrafiltration groupRenal functionCreatinine levelsPharmacologic therapyAdverse eventsEnd pointSafety of ultrafiltrationPrimary end pointSerious adverse eventsTreatment of patientsPersistent congestionDiuretic therapyCardiorenal syndromeRandomized trialsMean changePatientsBody weightWeight lossTherapySignificant differencesHigh rate